PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Participants

Interventions: Drug: PF-06835919 25 mg

First Posted Date: 2019-12-10

Last Posted Date: 2024-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT04193436

Locations: 🇨🇿
Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
🇸🇰
Summit Clinical Research, s.r.o.,, Bratislava, Slovakia
🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Open-Label Extension of Voxelotor

Phase 3

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Voxelotor

First Posted Date: 2019-12-06

Last Posted Date: 2024-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 162

Registration Number: NCT04188509

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Children's Healthcare of Atlanta Scottish Rite, Atlanta, Georgia, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 19 locations

Safety and Efficacy of Trastuzumab BS

Completed

Conditions: Gastric Cancer

Interventions: Drug: TRASTUZUMAB BS

First Posted Date: 2019-11-29

Last Posted Date: 2025-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT04181333

Locations: 🇯🇵
Pfizer, Tokyo, Japan

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Phase 2

Active, not recruiting

Conditions: Non-small-cell Lung Cancer
Advanced Malignancies

Interventions: Drug: PF-06801591

First Posted Date: 2019-11-29

Last Posted Date: 2025-02-18

Lead Sponsor: Pfizer

Target Recruit Count: 155

Registration Number: NCT04181788

Locations: 🇨🇳
Beijing Cancer hospital, Beijing, Beijing, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

and more 38 locations

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib + Letrozole
Drug: Letrozole
Drug: Palbociclib + an aromatase inhibitor

First Posted Date: 2019-11-25

Last Posted Date: 2024-08-23

Lead Sponsor: Pfizer

Target Recruit Count: 813

Registration Number: NCT04176354

Locations: 🇺🇸
Pfizer, New York, New York, United States

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Completed

Conditions: Metastatic Renal Cell Carcinoma (mRCC)

Interventions: Drug: sunitinib

First Posted Date: 2019-11-25

Last Posted Date: 2023-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 102

Registration Number: NCT04175262

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Etrasimod
Drug: Placebo

First Posted Date: 2019-11-21

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 1175

Registration Number: NCT04173273

Locations: 🇺🇸
Digestive Healthcare of Georgia, Atlanta, Georgia, United States
🇺🇸
Peachtree Allergy and Asthma Clinic - Chest X-rays and PFTs, Atlanta, Georgia, United States
🇺🇸
Ross Eyecare - Opthalmoscopy and OCT, Atlanta, Georgia, United States

and more 515 locations

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Phase 1

Terminated

Conditions: Gastrointestinal Tumors
Colorectal Adenocarcinomas
Gastric Adenocarcinomas
Esophageal Adenocarcinomas

Interventions: Drug: PF-07062119
Drug: Anti-PD1
Drug: Anti-VEGF

First Posted Date: 2019-11-20

Last Posted Date: 2025-01-16

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT04171141

Locations: 🇦🇺
The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇺🇸
UCLA Department of Medicine: Hematology-Oncology, Los Angeles, California, United States
🇺🇸
UCLA Hematology Oncology - Santa Monica, Santa Monica, California, United States

and more 16 locations

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Non-muscle Invasive Bladder Cancer

Interventions: Drug: PF-06801591
Drug: Bacillus Calmette-Guerin

First Posted Date: 2019-11-15

Last Posted Date: 2025-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 1070

Registration Number: NCT04165317

Locations: 🇺🇸
Urological Associates of Southern Arizona, P.C ., Tucson, Arizona, United States
🇺🇸
Urological Associates of Southern Arizona P.C., Tucson, Arizona, United States
🇺🇸
Arkansas Urology, Little Rock, Arkansas, United States

and more 175 locations

Real World Study Of The Clinical Profile And Treatment Outcomes Of Advanced Therapies For Ulcerative Colitis In Portugal

Withdrawn

Conditions: Ulcerative Colitis

First Posted Date: 2019-11-07

Last Posted Date: 2021-01-27

Lead Sponsor: Pfizer

Registration Number: NCT04156672

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy